Figure 1. Distribution of Modified Rankin Scale (mRS) Scores at 90 to 120 Days.

There was no significant difference between the tenecteplase and alteplase groups in the ordinal analysis of the mRS score, adjusted for age, sex, baseline stroke severity, occlusion location, and time from stroke symptom onset to needle as fixed-effects variables and site as a random-effects variable (adjusted common odds ratio, 0.91; 95% CI, 0.66-1.23). The mRS score ranges from 0 to 6, with 0 indicating no symptoms, 1 no clinically significant disability, 2 slight disability, 3 moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death.